Edition:
United Kingdom

Advanced Accelerator Applications SA (AAAP.OQ)

AAAP.OQ on NASDAQ Stock Exchange Global Select Market

81.70USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$81.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
156,009
52-wk High
$81.71
52-wk Low
$23.50

Latest Key Developments (Source: Significant Developments)

Advanced Accelerator Applications Announces Commencement Of Novartis Tender Offer
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Advanced Accelerator Applications Sa ::ADVANCED ACCELERATOR APPLICATIONS ANNOUNCES COMMENCEMENT OF NOVARTIS TENDER OFFER.ADVANCED ACCELERATOR APPLICATIONS - UNIT OF NOVARTIS COMMENCED CASH TENDER OFFER TO PURCHASE ALL OF CO'S ORDINARY SHARES FOR $41.00/SHARE, $82.00/ADS.ADVANCED ACCELERATOR APPLICATIONS SA - OFFER WILL EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, ON JANUARY 19, 2018, UNLESS EXTENDED.  Full Article

Advanced Accelerator Applications Board Recommends $3.9 Bln All Cash Tender Offer By Novartis
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Advanced Accelerator Applications Sa ::ADVANCED ACCELERATOR APPLICATIONS BOARD OF DIRECTORS RECOMMENDS $3.9 BILLION ALL CASH TENDER OFFER BY NOVARTIS.ADVANCED ACCELERATOR APPLICATIONS - CO'S BOARD RECOMMENDS $3.9 BILLION ALL CASH TENDER OFFER BY NOVARTIS.  Full Article

Advanced Accelerator Applications reports qtrly loss per share EUR​ ‍0.26
Friday, 17 Nov 2017 

Nov 17 (Reuters) - Advanced Accelerator Applications SA :Advanced Accelerator Applications reports 39% sales growth for third quarter 2017.Q3 sales rose 39 percent to $43.9 million.Advanced Accelerator Applications SA qtrly loss per share EUR​ ‍0.26.  Full Article

Advanced Accelerator Applications reports 24.4% sales growth in Q2
Wednesday, 31 Aug 2016 

Advanced Accelerator Applications Sa : Advanced Accelerator Applications reports 24.4% sales growth in the second quarter of 2016 . Q2 sales rose 24.4 percent to eur 27.64 million .Qtrly loss per share eur 0.02.  Full Article

Advanced Accelerator Applications announces FDA priority review for Lutathera
Monday, 27 Jun 2016 

Advanced Accelerator Applications Sa : Advanced accelerator applications announces FDA priority review for Lutathera . FDA has accepted company's new drug application and granted priority review for Lutathera .Prescription drug user fee act (PDUFA) target action date is December 28, 2016.  Full Article

Cardinal Health to prepare NETSPOT doses for Advanced Accelerator Applications
Thursday, 9 Jun 2016 

:Advanced Accelerator Applications S.A. says selected Cardinal Health to supply Gallium 68 dotatate doses to u.s. Hospitals and imaging centers.  Full Article

Advanced Accelerator Applications gets FDA approval of NetSpot
Thursday, 2 Jun 2016 

Advanced Accelerator Applications : Advanced Accelerator Applications Announces FDA Approval Of Netspot(Tm) (Somakit-tate), a kit for the preparation of Gallium GA 68 Dotatate for neuroendocrine tumor detection .Advanced Accelerator Applications SA says Netspot TM will be made available to US market as soon as possible.  Full Article

Advanced Accelerator Q1 sales rose 29.6 pct to EUR26.92 mln
Tuesday, 31 May 2016 

Advanced Accelerator Applications SA : Advanced accelerator applications reports 29.6 pct sales growth in the first quarter of 2016 .Q1 sales rose 29.6 percent to EUR 26.92 million.  Full Article

Advanced Accelerator Applications SA inks deal with Johns Hopkins University to develop prostate cancer drug
Monday, 11 Jan 2016 

Advanced Accelerator Applications SA:Signs exclusive license agreement with johns hopkins university to develop psma receptor ligand in prostate cancer.  Full Article

Advanced Accelerator Applications SA buys the IDB Group
Thursday, 7 Jan 2016 

Advanced Accelerator Applications SA:Acquires the idb group.Says has acquired 100% of the shares of the idb group.  Full Article